Ardelyx Inc (NAS:ARDX)
$ 5.21 0.4 (8.32%) Market Cap: 1.23 Bil Enterprise Value: 1.05 Bil PE Ratio: 0 PB Ratio: 7.80 GF Score: 70/100

Ardelyx Inc FDA Update On Tenapanor For Hyperphosphatemia NDA Corporate Call Transcript

Jul 29, 2021 / 09:00PM GMT
Release Date Price: $1.71 (-1.16%)
Operator

Good afternoon, and welcome to Ardelyx's conference call. (Operator Instructions)

As a reminder, today's call is being recorded. I would now like to turn the call over to Kimia Keshtbod, Manager of Corporate Communications. You may begin.

Kimia Keshtbod
Ardelyx, Inc. - Manager of Corporate Communications & IR

Thank you, and good afternoon, everyone. During this call, we will refer to the press release issued today, which is available in the Investors section of the company's website at ardelyx.com. On the call with me today are Mike Raab, President and CEO, with prepared remarks. Dr. David Rosenbaum, Chief Development Officer; Susan Rodriguez, Chief Commercial Officer; Justin Renz, Chief Financial Officer; and Rob Blanks, Chief Regulatory Affairs and Quality Assurance Officer, will join us for the question-and-answer period.

During this call, we will be making forward-looking statements that are subject to risks and uncertainties. Our actual results may differ materially from those described. We encourage you to review our risk factors

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot